INTRODUCTION
Hyperprolactinemia (HP) is the most common hypothalamic-pituitary problem in clinical endocrinology. Besides prolactinomas (macro-micro prolactinomas) hyper PRL can be caused by incidental thyroid (pseudohiper PRL) and functional hyper PRL (iatrogenic, primary hypothyroidism, PCOS, chronic liver and kidney stress). Hyper PRL direct effect on ovarian granulosa cells disrupts steroidogenesis and flavored androgens into estrogens, and directly inhibits GnRH and causes hypogonadotropy hypogonadism. The consequences are secondary amenorrhea/ galactorrhea, infertility and habitual abortion (1) .
. In 90% of women are micro prolactinomas tumor, while in men macro prolactinomas (2). Prolactinoma are the most common type of pituitary tumors and are associated with galactorrheom, amenorrhea and hyperprolactinemia. Size of serum prolactin is linearly correlated with tumor size. Diagnosis can be easily set up on the basis of elevated basal prolactin and using MRI pituitary region (3) . Dopamine agonists (Bromocriptine, Cabergolin) are drugs of first choice in the treatment of prolactinomas and thus infertility treatment in infertile women. Dopamine agonists (Bromocriptine) normalized hyperprolactinemia in 72-92% of cases, normalized gonadal dysfunction in more than 90%, reduce the tumor mass in 60-70% of cases. Resistance to bromocriptine occurs in 10-20% of patients (4) . The purpose of this study was to determine the effects of bromocriptine in normalizing prolactin, gonadal function, tumor mass and infertility.
MATeRIALS AND MeTHODS
Patients: A prospective controlled clinical study included testing 30 infertile women with prolactinomas. The study was conducted from January 2010 until January 2012 in outpatient polyclinics institutions TK. All infertile patients were determined factor infertility micro-macro prolactinomas. Criteria for inclusion were infertile women with clinical, hormonal and MRI demonstrated prolactinoma. The studies excluded infertile women with other causes hyper PRL (pseudo hyperprolactinemia and functional hyperprolactinemia) and infertile women with other infertility factors (uterine, tubal factor, male factor unexplained infertility). All infertile women have a certain baseline: TSH, prolactin, FSH, LH and estradiol. All patients underwent MRI the pituitary gland was scanned by camera 1.5 T before and 6, 12 and 24 months after treatment with bromocriptine. The maximal tumor diameter was obtained as the mean of all measurements and is expressed in millimeters. Primary objective was to determine the clinical signs and symptoms of hyperprolactinemia, the effect of prolactin on gonadal function and maximal tumor diameter. The secondary objective was to determine the effects of bromocriptine effects on the size of prolactin, gonadal function, and tumor size. Patients were randomized into two groups: Group A: 10 patients with macro prolactinomas, and Group B: 20 patients with micro prolactinomas. Both groups were treated with bromocriptine (Bromergon, 2.5 mg tablets, Lek, Ljubljana, Slovenia), at a dose of 2.5 to 20 mg/day to normalize prolactin (less than 10 µg/L). Prolactin level was measured baseline, then monthly for 24 months. FSH, LH, estradiol were measured baseline and quarterly intervals, for a period of 24 months. 
ReSULTS
From a total of 30 infertile women with tumor hiperPRL (macro-micro prolactinomas), 10 of them had macroadenomas, while 20 had microadenomas. Clinical signs and symptoms in patients with micro prolactinomas are: mean age 27.1 years, 20% had headache, BMI 26.6 kg/m 2 , even in one patient was not observed visula field defects (0%) had galactorrhea, 85% galactorrhea / amenorrhea, 80 % irregular menstruation 80%, infertility 80%, 0% had hypopituitarism and duration of infertility was 4.2 years (Table 1) . Clinical signs and symptoms in patients with macro prolactinomas: mean age 26.9 years, 40% had a headache, 50% of visula field defects, BMI 27.4 kg/ m 2 , 90% galactorrhea, 80% galactorrhea / amenorrhea, 90% irregular menstrual cycle, 90% infertility, 50% patients had hypopituitarism, duration of infertility amounted to 5.6 years ( Table 1) .
Comparison of basal values of PRL, FSH, LH, estradiol and progesterone are shown in Table 2 
DISCUSSION
Prolactinomas are the most common tumors of the pituitary gland, leading to disturbances in the hypothalamic-pituitary-gonadal axes (3) . Divided by the size of the macroprolactinoma and micro prolactinoma. Macro prolactinomas are defined if the serum prolactin is greater than 200 µg/L, a pituitary tumor with diameter greater than 1 cm, measured by MRI, while micro prolactinomas are defined if serum prolactin is less than 200 µg / L and pituitary tumor diameter measured MRI, less than 1 cm (5). Tumor size was a direct linear correlation with hyperprolactinemia (3) of the women at the time of diagnosis of hyperprolactinemia are detected in 90% of cases of micro prolactinomas, and in 10% of cases of macroprolactinoma, while men more often macroprolactinoma. Slightly higher frequency of micro prolactinoma in women is the cause of re- Legend: The results are expressed as mean ± SD, percentag e%, statistical significance p<0.05 level of significance, and ap<0.05, bp<0.01, cp<0.001(basal), for the group with Responsive Vs. Resistant; ap<0.05, bp<0.01, cp<0.001, for the group with Responsive Vs. Resistant(*), pRL-prolactin. . * hormone levels after 2-year treatment bromocriptine. Table 5 . Response to bromocriptine in a 24-month treatment of infertile women with microprolactinomas productive disorders (6, 7) . Symptoms that occur with prolactinoma are galactorrhea, amenorrhea, gonadal dysfunction, infertility, and if present macroprolactinoma can occur and symptoms such as headache, visual disturbances, panhypopituitarism (1, 7) . Prolactin direct effect on GnRH leads to dopamine blocking activity, and inhibition of the action of dopamine is absent, so that hyperprolactinemia, and further inhibition of GnRH leads to failure gonadotropin and estradiol. Prolactin direct effect on ovarian granulosa cells disrupts ovarian steroidogenesis, and it does not come up to the conversion of androgens to estrogens, and decreased estradiol (8, 9). The same mechanism leads to luteal phase defect, causing anovulation (10) . Consequence of hyperprolactinemia in women's reproductive infertility, and the existence of occult hyperprolactinemia are recurrent abortions (1, 11) . The first line of treatment micro prolactinomas are antagonists of dopamine (bromocriptine, cabergolin), are effective in the treatment of prolactinomas in both sexes (12) . Bromocriptine was the first dopamine agonist to be introduced into clinical practice. It is a semisynthetic ergot derivatives of ergoline, a D2 receptor agonist with antagonist properties at D1 receptors. Its elimination half life is relatively short (3.3 hours), and therefore it usually has to be taken 2 or 3 times daily (13) . Those in the 75-92% of normalized prolactin levels, establishing gonadal function in more than 90% of cases, reduce the tumor mass in 60-70% of cases and establish normal pituitary function. Approximately 10-26% of tumors develop resistance to therapy bromocriptine and 31-69% in the cabergolin therapy (4). In such cases prolactinoma require surgical treatment. Surgical resection of the adenoma is usually associated with a risk of recurrence in all patients. Hyperprolactinemia recurs one to five years after surgery in 10% -50% of patients with micro prolactinomas and in 20% -90% of patients with macro prolactinomas (14) . Results of this study showed that the prevalence micro prolactinoma in reproductive women were 70% and 30% of macro prolactinomas. The predominant symptoms in existence macroprolactinoma were galactorrhea in 87.3%, galactorrhea-amenorrhea in 81.6%, panhypopituitarism in 52% of cases, irregular menstruation in 82% of infertility in 83% patients. In case of micro prolactinoma symptoms were galactorrhea in 83.3% of cases, galactorrhoea -amenorrhea in 82.3%, irregular menstrual periods were detected in 74.2% and 75.3% of infertility in women. The results are explained by hyperprolactinemia acts directly on the hypothalamus and pituitary gland and leads to secondary hypogonadism that causes these symptoms, while symptoms such as headache, visual disturbances and panhypopituitarism due to the pressure of the tumor mass on the surrounding structures in the hypothalamic-pituitary region. Our results are consistent with the results of other authors (15, 16) . The results of our study indicate that the macro-and micro prolactinomas lead to significantly reduced (p <0.05) values of FSH, LH, estradiol and luteal progesterone. The results of this study are consistent with results of other authors (11, 16) . Results of this study indicated that bromocriptine therapy significantly reduced the prolactin p<0.05 in the macro-and micro prolactinomas. Bromocriptine therapy has significantly raised the value of FSH, LH, estradiol and luteal progesterone and led to the normalization of gonadal function in 90% of patients. After a 24-month treatment with bromocriptine there was a significant reduction (p<0.05), maximal tumor diameter in 83% of cases in sensitive prolactinomas and in 49.8% of cases of resistant prolactinomas. Results Colaoa and associates suggest that dopamine agonist (cabergolin) for a period of 24 months led to a significant reduction in the maximal diameter of the tumor (p<0.01) in micro-macro prolactinomas. Colao said that there were macro-micro prolactinomas that are sensitive and resistant to dopamine agonist therapy (16).
CONCLUSION
Micro-macro prolactinomas are cause of gonadal dysfunction, amenorrhea and infertility. Bromocriptine therapy is the first line of treatment micro prolactinoma and macroprolactinoma. Therapeutic effects are normalizing menstrual cycle in over 90% of cases and restore fertility in 60% of cases. Following the effect of therapy is to reduce the tumor mass. In 10-30% of infertile women with micro-macro prolactinomas there is resistance to therapy, bromocriptine, and such cases require surgical treatment.
